EUVIMEDEUVIMED entdecken
Crossref

Reevaluating regorafenib: Do we need the full dose?

Beliz Bahar Karaoğlan, Erman Akkus, Mehmet Kayaalp, Buse Arslan Özçobanlar, Güngör Utkan

Turkish Journal of Clinics and Laboratory · 28.03.2026 · (1)

DOI: 10.18663/tjcl.1874059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Clinics and Laboratory, online erschienen am 28.03.2026. Verfasst von Beliz Bahar Karaoğlan und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Ankara University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Regorafenib is a standard treatment for metastatic colorectal cancer (mCRC), typically administered at a dose of 160 mg/day. This study evaluates the efficacy and tolerability of lower doses of regorafenib compared to the standard dose.Material and Methods: A total of 58 mCRC patients were divided into two groups: low-dose (≤120 mg/day) and high-dose (>120 mg/day). We assessed disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Dose modifications and treatment discontinuations were recorded.

Results

58 patients with a median age of 57 years were included. Regorafenib was administered as a median fourth-line treatment, with 34 patients in the low-dose group and 24 in the high-dose group. Disease control rates were 37.9%, with no significant difference between low-dose and high-dose groups (35.3% vs. 41.7%, P=0.625). Median PFS was similar between the groups [3.3 months (95% CI: 2.2-4.3) vs. 4.1 months (95% CI: 2.3-5.8), P=0.695]. OS was also comparable across groups [7.8 months (95% CI: 5.8-9.7) vs. 10.3 months (95% CI: 5.1-15.5), P=0.213]. AEs were reported in 89.6% of patients, with a significantly higher rate of dose reductions or discontinuations in the high-dose group (41.7% vs. 11.8%, P=0.013).

Conclusion

Lower doses of regorafenib (≤120 mg/day) provide comparable efficacy and similar disease control rates to the standard dose. The high-dose regimen is associated with greater tolerability issues, suggesting that lower doses may be a viable alternative for better patient management.

Förderung

  • Ankara University

Zitieren

APA

Karaoğlan, B. B., Akkus, E., Kayaalp, M., Özçobanlar, B. A., & Utkan, G. (2026). Reevaluating regorafenib: Do we need the full dose?. Turkish Journal of Clinics and Laboratory. https://doi.org/10.18663/tjcl.1874059

Vancouver

Karaoğlan BB, Akkus E, Kayaalp M, Özçobanlar BA, Utkan G. Reevaluating regorafenib: Do we need the full dose?. Turkish Journal of Clinics and Laboratory. 2026. doi:10.18663/tjcl.1874059

BibTeX
@article{Karaolan2026,
  author = {Karaoğlan, Beliz Bahar and Akkus, Erman and Kayaalp, Mehmet and Özçobanlar, Buse Arslan and Utkan, Güngör},
  title = {Reevaluating regorafenib: Do we need the full dose?},
  journal = {Turkish Journal of Clinics and Laboratory},
  year = {2026},
  number = {1},
  doi = {10.18663/tjcl.1874059}
}
Kostenlos starten →